Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17256387 | Hyaluronic Acid-Based Zwitterionic Polymer Brush, Preparation Method Thereof, and Use Thereof | December 2020 | January 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17105587 | Composition of corneal implantation, and the use and preparation method thereof | November 2020 | October 2024 | Abandon | 46 | 3 | 1 | No | No |
| 17054137 | NOVEL CROP NUTRITION AND FORTIFICATION COMPOSITION | November 2020 | July 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17035339 | COMPOSITIONS AND METHODS FOR TARGETING CELLS | September 2020 | July 2024 | Allow | 46 | 4 | 1 | Yes | No |
| 17024755 | Horticulture Additive | September 2020 | May 2025 | Abandon | 55 | 4 | 1 | No | No |
| 16999841 | RADIOPAQUE MULTI-ARMED POLYMERS AND COMPOSITIONS, SYSTEMS AND METHODS PERTAINING TO THE SAME | August 2020 | January 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 15733436 | NOVEL ANTHRANILAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAME | July 2020 | October 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16920341 | PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANES | July 2020 | August 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16447716 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | June 2019 | October 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16427560 | RESIDENT ARTICLES FOR GRAM-LEVEL DOSING | May 2019 | April 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 15838977 | METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTION | December 2017 | April 2019 | Allow | 16 | 1 | 1 | Yes | No |
| 15570276 | ANTIBACTERIAL NANOFIBRES | October 2017 | July 2020 | Abandon | 33 | 9 | 1 | No | No |
| 15542793 | COSMETIC COMPOSITION FOR ORAL ADMINISTRATION FOR REINFORCING THE SKIN BARRIER | July 2017 | September 2018 | Allow | 14 | 3 | 0 | Yes | No |
| 15582076 | HAIR-TREATMENT COMPOSITIONS COMPRISING A POLYURETHANE LATEX POLYMER AND CATIONIC COMPOUND | April 2017 | May 2025 | Allow | 60 | 10 | 1 | Yes | Yes |
| 15492146 | METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTION | April 2017 | April 2019 | Allow | 24 | 2 | 1 | Yes | No |
| 15483006 | ANTIBACTERIAL SPECTACLE PART AND ANTIBACTERIAL TREAMENT METHOD | April 2017 | July 2018 | Allow | 15 | 2 | 1 | Yes | No |
| 15393850 | 6-ACYL-1,2,4-TRIAZINE-3,5-DIONE DERIVATIVE AND HERBICIDES | December 2016 | May 2018 | Allow | 16 | 2 | 1 | No | No |
| 15322776 | Antitumor Composition Based on Hyaluronic Acid and Inorganic Nanoparticles, Method of Preparation Thereof and Use Thereof | December 2016 | February 2020 | Allow | 37 | 4 | 1 | Yes | No |
| 15361426 | CRYSTALLINE COATING AND RELEASE OF BIOACTIVE AGENTS | November 2016 | July 2018 | Allow | 20 | 2 | 1 | Yes | No |
| 15079171 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | March 2016 | January 2018 | Allow | 22 | 3 | 0 | Yes | No |
| 14919962 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF | October 2015 | August 2017 | Allow | 22 | 1 | 0 | Yes | No |
| 14776827 | METHODS OF IDENTIFICATION AND USE OF NEMATICIDE COMPOUNDS | September 2015 | September 2019 | Allow | 48 | 2 | 1 | Yes | No |
| 14756288 | Acne formulation having stabilized ascorbic acid and other actives | August 2015 | May 2017 | Allow | 21 | 1 | 0 | Yes | No |
| 14762286 | AGROCHEMICAL COMPOSITION, METHOD FOR ITS PREPARATION AND USE THEREOF | July 2015 | September 2019 | Allow | 50 | 6 | 1 | Yes | No |
| 14742936 | PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME | June 2015 | June 2017 | Allow | 24 | 1 | 1 | Yes | No |
| 14702843 | Method for Oxygen Treatment of Intact Skin | May 2015 | October 2016 | Allow | 17 | 1 | 0 | Yes | No |
| 14667826 | ABUSE DETERRENT IMMEDIATE RELEASE BIPHASIC MATRIX SOLID DOSAGE FORM | March 2015 | December 2016 | Allow | 21 | 2 | 0 | Yes | No |
| 14427846 | A SOFT GELATIN ENCAPSULATED PHARMACEUTICAL COMPOSITION OF CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID IN FREE ACID FORM AND CIS-7,10,13,16,19-DOCOSAPENTAENOIC ACID IN FREE ACID FORM | March 2015 | March 2019 | Allow | 48 | 5 | 1 | Yes | No |
| 14553187 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | November 2014 | January 2018 | Allow | 38 | 3 | 0 | Yes | No |
| 14526646 | IMPRINTED PARTICLE STRUCTURE | October 2014 | July 2016 | Allow | 21 | 2 | 0 | Yes | No |
| 14513333 | Insecticide-Containing Netlike Fabric | October 2014 | June 2016 | Allow | 20 | 2 | 0 | Yes | No |
| 14241166 | DRESSINGS THAT CONTAIN ACTIVE SUBSTANCE | June 2014 | January 2019 | Allow | 58 | 2 | 1 | No | Yes |
| 14280696 | FILM COMPOSITION AND METHODS FOR PRODUCING THE SAME | May 2014 | September 2019 | Allow | 60 | 6 | 1 | Yes | No |
| 14342886 | POLYAMIDE COMPOSITIONS FOR PERSONAL CARE | April 2014 | February 2016 | Allow | 24 | 1 | 1 | Yes | No |
| 14221646 | WATER-BASED GEL COSMETIC COMPOSITIONS CONTAINING EMULSIFIER | March 2014 | August 2016 | Allow | 28 | 3 | 0 | No | No |
| 13999696 | DELIVERY SYSTEM HAVING STABILIZED ASCORBIC ACID AND OTHER ACTIVES | March 2014 | May 2015 | Allow | 14 | 2 | 0 | Yes | No |
| 14116816 | DRYABLE ADHESIVE COATING | March 2014 | November 2015 | Allow | 24 | 1 | 1 | Yes | No |
| 14186146 | Ophthalmologic Irrigation Solutions and Method | February 2014 | December 2015 | Allow | 22 | 2 | 0 | Yes | No |
| 14174442 | THERMOPLASTIC PASTE FOR REPAIRING LIVING TISSUES | February 2014 | March 2016 | Allow | 25 | 2 | 1 | Yes | No |
| 14057847 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF | October 2013 | July 2015 | Allow | 21 | 2 | 0 | Yes | No |
| 14055959 | PULMONARY DELIVERY FOR LEVODOPA | October 2013 | June 2015 | Allow | 20 | 1 | 0 | No | No |
| 13816000 | Delivery system having stabilized ascorbic acid and other actives | March 2013 | May 2015 | Allow | 26 | 2 | 0 | Yes | No |
| 13785626 | Degradable Therapeutic Delivery Device | March 2013 | March 2014 | Allow | 12 | 2 | 0 | Yes | No |
| 13747165 | COPPER SALTS OF ION EXCHANGE MATERIALS FOR USE IN THE TREATMENT AND PREVENTION OF INFECTIONS | January 2013 | July 2015 | Allow | 30 | 2 | 1 | Yes | No |
| 13739020 | COMPOSITIONS AND METHODS FOR AUGMENTATION AND REGENERATION OF LIVING TISSUE IN A SUBJECT | January 2013 | September 2014 | Allow | 20 | 2 | 0 | Yes | No |
| 13498436 | FUNCTIONALIZED NANODIAMOND REINFORCED BIOPOLYMERS | July 2012 | August 2015 | Allow | 41 | 2 | 1 | Yes | No |
| 13266992 | AGROCHEMICAL FORMULATIONS OF MICROCAPSULES FOR COMPOUNDS CONTAINING CARBOXAMIDE GROUPS | January 2012 | February 2015 | Allow | 39 | 2 | 1 | Yes | No |
| 13137560 | DRUG-ELUTING STENT | August 2011 | July 2013 | Allow | 23 | 1 | 0 | Yes | No |
| 13142576 | PATCH PRODUCTION TECHNOLOGY | June 2011 | May 2014 | Allow | 35 | 2 | 1 | Yes | No |
| 13119756 | DRUG ELUTING SUPERHYDROPHOBIC COATINGS | May 2011 | April 2014 | Allow | 37 | 1 | 2 | Yes | No |
| 13086498 | INSECTICIDE-CONTAINING NETLIKE FABRIC | April 2011 | September 2014 | Allow | 41 | 3 | 1 | Yes | No |
| 13022776 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | February 2011 | March 2014 | Allow | 37 | 4 | 0 | Yes | No |
| 12993985 | THERMOPLASTIC PASTE FOR REPAIRING LIVING TISSUES | January 2011 | October 2013 | Allow | 34 | 0 | 1 | Yes | No |
| 12914456 | PERCUTANEOUSLY ABSORBABLE PREPARATION, PERCUTANEOUSLY ABSORBABLE PREPARATION HOLDING SHEET, AND PERCUTANEOUSLY ABSORBABLE PREPARATION HOLDING EQUIPMENT | October 2010 | May 2013 | Allow | 31 | 2 | 0 | Yes | No |
| 12908686 | Thermorod For Active Drug Release and Method For Manufacturing The Same | October 2010 | August 2014 | Allow | 46 | 2 | 0 | Yes | No |
| 12867943 | SUPERABSORBENT COMPOSITION WITH METAL SALICYLATE FOR ODOR CONTROL | September 2010 | February 2014 | Allow | 42 | 4 | 1 | Yes | No |
| 12865464 | Core-Shell Type Zinc Oxide Microparticle or Dispersion Containing the Microparticle, and Production Process and Use of the Microparticle or the Dispersion | August 2010 | October 2013 | Allow | 38 | 2 | 1 | Yes | No |
| 12824946 | COSMETIC COMPOSITIONS COMPRISING A POLAR MODIFIED POLYMER AND A TACKIFIER | June 2010 | August 2014 | Allow | 50 | 5 | 0 | Yes | No |
| 12703946 | MEDICAL DEVICES HAVING POLYMERIC NANOPOROUS COATINGS FOR CONTROLLED THERAPEUTIC AGENT DELIVERY AND A NONPOLYMERIC MACROPOROUS PROTECTIVE LAYER | February 2010 | February 2014 | Allow | 48 | 3 | 1 | Yes | No |
| 12689956 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF | January 2010 | June 2013 | Allow | 41 | 3 | 1 | Yes | No |
| 12639403 | ORGANIC POLYMER-INORGANIC FINE PARTICLE ANTIMICROBIAL COMPOSITES AND USES THEREOF | December 2009 | June 2012 | Allow | 30 | 1 | 1 | Yes | No |
| 12591700 | ORALLY ADMINISTERED AGENT AND AN ORALLY ADMINISTERED AGENT/SUPPORTING SUBSTRATE COMPLEX | November 2009 | May 2012 | Allow | 30 | 1 | 0 | Yes | No |
| 12532486 | Implant Material Based On A Polymer System And The Use Thereof | September 2009 | June 2014 | Allow | 57 | 4 | 0 | Yes | No |
| 12519973 | AZOLYLMETHYLOXIRANES, THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI, AND COMPOSITIONS COMPRISING THEM | June 2009 | April 2011 | Allow | 22 | 1 | 1 | No | No |
| 12445478 | EDIBLE FOAM PRODUCT FOR THE TREATMENT OR PREVENTION OF OBESITY | April 2009 | September 2014 | Allow | 60 | 4 | 1 | Yes | No |
| 12226524 | PHARMACEUTICAL COMPOSITIONS COMPRISING NON-STEROIDAL ANTIINFLAMMATORY DRUG, ANTIPYRETIC-ANALGESIC DRUG AND PROTON PUMP INHIBOTOR | March 2009 | April 2014 | Allow | 60 | 4 | 0 | Yes | No |
| 12304069 | USE OF NANOMATERIALS BASED ON TITANIUM DIOXIDE AND ZIRCONIUM DIOZIDE AS COATINGS FOR OSTEOINTEGRATED BIOMEDICAL PROSTHESES, AND OSTEOINTEGRATED BIOMEDICAL PROSTHESES PREPARED THEREWITH | February 2009 | December 2011 | Allow | 36 | 1 | 1 | No | No |
| 12093548 | DEODORIZING SUPER-ABSORBENT COMPOSITION | November 2008 | October 2013 | Allow | 60 | 4 | 1 | Yes | No |
| 12232304 | Topical anti-inflammatory compositions comprising O/W emulsions containing pro-penetrating glycols | September 2008 | June 2013 | Allow | 57 | 2 | 0 | Yes | No |
| 12232305 | TOPICAL ANTI-INFLAMMATORY COMPOSITIONS COMPRISING O/W EMULSIONS CONTAINING PRO-PENETRATING GLYCOLS | September 2008 | June 2013 | Allow | 57 | 2 | 0 | Yes | No |
| 12182066 | BIOLOGICALLY DEGRADABLE COMPOSITIONS FOR MEDICAL APPLICATIONS | July 2008 | May 2014 | Allow | 60 | 4 | 1 | No | Yes |
| 12093671 | FUNCTIONAL NANOMATERIALS WITH ANTIBACTERIAL AND ANTIVIRAL ACTIVITY | May 2008 | December 2011 | Allow | 43 | 1 | 1 | No | No |
| 11885454 | Filmy Compositions | August 2007 | November 2013 | Allow | 60 | 4 | 0 | Yes | No |
| 11816744 | SUSTAINED RELEASE COMPOSITION OF PROTEIN DRUG | August 2007 | June 2011 | Allow | 46 | 2 | 0 | Yes | No |
| 11786629 | METHOD OF MAKING UP NAILS | April 2007 | March 2011 | Allow | 47 | 1 | 0 | No | No |
| 11660664 | Mucosal or Cutaneous Medicinal or Hygiene System | February 2007 | November 2013 | Allow | 60 | 3 | 0 | No | No |
| 11702970 | METHODS FOR TREATING INFLAMMATORY DISEASE BY ADMINISTERING ALDEHYDES AND DERIVATIVES THEREOF | February 2007 | June 2010 | Allow | 41 | 2 | 1 | Yes | No |
| 11628744 | Dry Composition for Oral Ingestion and Gel Composition Prepared Just Before Use for Oral Ingestion | December 2006 | June 2015 | Allow | 60 | 6 | 0 | Yes | No |
| 10599729 | Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof | October 2006 | April 2013 | Allow | 60 | 2 | 0 | Yes | No |
| 11514891 | Percutaneous absorption-type pharmaceutical preparations | September 2006 | April 2013 | Allow | 60 | 2 | 0 | Yes | No |
| 10551654 | COMPOSITION FOR PRODUCTION OF A STERILIZER AND A PROCESS FOR PRODUCING ORGANIC PERACID | July 2006 | November 2010 | Allow | 60 | 3 | 0 | Yes | No |
| 11433013 | Aqueous dispersions and solutions of difficult to dissolve materials and methods of their preparation | May 2006 | February 2013 | Allow | 60 | 2 | 0 | No | No |
| 11405262 | Degradable therapeutic delivery device | April 2006 | November 2012 | Allow | 60 | 3 | 1 | Yes | No |
| 11337247 | MEDICAMENT AND METHOD OF TREATMENT OF PATIENTS WITH HEAVY METALS | January 2006 | October 2009 | Allow | 45 | 3 | 1 | Yes | No |
| 10494526 | METHOD FOR PREPARING GELS | December 2004 | March 2010 | Allow | 60 | 2 | 0 | No | No |
| 10495490 | METAL OXIDE COMPOSITION | December 2004 | December 2011 | Allow | 60 | 4 | 0 | Yes | No |
| 10993338 | Water resistant sunscreen and insect repellant towel | November 2004 | April 2013 | Allow | 60 | 8 | 0 | Yes | No |
| 10969998 | ADSORBENT FOR ORAL ADMINISTRATION, AND AGENT FOR TREATING OR PREVENTING RENAL OR LIVER DISEASE | October 2004 | September 2014 | Allow | 60 | 7 | 1 | Yes | No |
| 10972063 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | October 2004 | March 2011 | Allow | 60 | 5 | 1 | Yes | Yes |
| 10505415 | NANOSCALE ZINC OXIDE, PROCESS FOR ITS PRODUCTION AND USE | August 2004 | December 2009 | Allow | 60 | 3 | 0 | Yes | No |
| 10493693 | ANTIPRURITIC AGENT | April 2004 | January 2010 | Allow | 60 | 3 | 1 | Yes | No |
| 10475785 | GASTRIC JUICE-RESISTANT DEVICE FOR RELEASING MUCOADHESIVE ACTIVE SUBSTANCE EXCIPIENTS, AND METHOD FOR PRODUCING THIS GASTRIC JUICE-RESISTANT DEVICE | December 2003 | March 2011 | Allow | 60 | 7 | 0 | Yes | Yes |
| 10684893 | DEGRADABLE POLY(ETHYLENE GLYCOL) HYDROGELS WITH CONTROLLED HALF-LIFE AND PRECURSORS THEREFOR | October 2003 | February 2011 | Allow | 60 | 7 | 1 | Yes | Yes |
| 10657550 | Formulations and methods for treating rhinosinusitis | September 2003 | August 2014 | Allow | 60 | 10 | 1 | Yes | Yes |
| 10652283 | Low viscosity filler composition of boron nitride particles of spherical geometry and process | August 2003 | September 2016 | Allow | 60 | 9 | 0 | Yes | Yes |
| 10627990 | TRANSDERMAL DELIVERY SYSTEM | July 2003 | June 2012 | Allow | 60 | 8 | 0 | Yes | Yes |
| 10311913 | SUSTAINED-RELEASE PREPARATIONS OF QUINOLONE ANTIBIOTICS AND METHOD FOR PREPARATION THEREOF | May 2003 | February 2010 | Allow | 60 | 8 | 0 | Yes | Yes |
| 10379720 | SPHERICAL COMPOSITE PARTICLES AND COSMETICS WITH THE PARTICLES BLENDED THEREIN | March 2003 | January 2010 | Allow | 60 | 6 | 0 | No | Yes |
| 10304793 | ADHESIVE BLOCK ETHYLENIC COPOLYMERS, COSMETIC COMPOSITIONS CONTAINING THEM AND COSMETIC USE OF THESE COPOLYMERS | November 2002 | September 2012 | Allow | 60 | 11 | 1 | Yes | Yes |
| 10078805 | BIOCOMPATIBLE COMPOUNDS FOR SUSTAINED RELEASE PHARMACEUTICAL DRUG DELIVERY SYSTEMS | February 2002 | November 2009 | Allow | 60 | 9 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VANHORN, ABIGAIL LOUISE.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VANHORN, ABIGAIL LOUISE works in Art Unit 1636 and has examined 103 patent applications in our dataset. With an allowance rate of 96.1%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner VANHORN, ABIGAIL LOUISE's allowance rate of 96.1% places them in the 85% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by VANHORN, ABIGAIL LOUISE receive 3.50 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VANHORN, ABIGAIL LOUISE is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +21.1% benefit to allowance rate for applications examined by VANHORN, ABIGAIL LOUISE. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 38.7% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 140.0% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.7% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.